Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    PANCREATIC GS 6624 MARYLAND
Show Display Options
Rank Status Study
1 Active, not recruiting A Study to Evaluate the Efficacy and Safety of Simtuzumab Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Condition: Pancreatic Cancer
Interventions: Drug: Simtuzumab;   Drug: Gemcitabine;   Drug: Placebo to match simtuzumab

Indicates status has not been verified in more than two years